...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies.
【24h】

Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies.

机译:肾慢性同种异体移植排斥反应发展的早期预后,可通过人类方案活检的基因表达谱进行。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Chronic allograft rejection (CR) is the major cause of failure of long-term graft survival and is so far irreversible. Early prognosis of CR by molecular markers before overt histologic manifestation would be a valuable aid for the optimization of treatment regimens and the design of clinical CR trials. Oligonucleotide microarray-based approaches have proven to be useful for the diagnosis and prognosis of a variety of diseases and were chosen for the unbiased identification of prognostic biomarkers. METHODS: Renal allograft biopsies were taken at month 6 posttransplantation (PT) from two groups who were, at that time, healthy recipients: one group developed CR at month-12 PT, the other group remained healthy. Gene expression profiles from the two groups at month-6 PT biopsies were analyzed to identify differentially expressed genes with prognostic value for CR development at month 12. RESULTS: A set of 10 genes was identified that showed differential expression profiles between the two patient groups and had a complete separation of the 15% to 85% quantile range for each individual gene. This set of genes was sufficient to allow the correct prediction of the occurrence or nonoccurrence of CR in 15 of 17 (88%) patients using cross-validation (occurrence for a patient was predicted on the basis of the other patients' data only). In addition, a correct prediction could be made that a recipient with a normal biopsy 12 months PT developed CR within the following 6 months. CONCLUSIONS: Identified expression patterns seem to be highly prognostic of the development of renal CR.
机译:背景:慢性同种异体移植排斥(CR)是长期移植存活失败的主要原因,并且迄今为止是不可逆的。在明显的组织学表现之前,通过分子标记物对CR进行早期预后将为优化治疗方案和设计临床CR试验提供有价值的帮助。已证明基于寡核苷酸微阵列的方法可用于多种疾病的诊断和预后,并被选择用于预后生物标志物的无偏鉴定。方法:在移植后第6个月,从两组健康的受者中进行了肾脏同种异体移植活检:一组在PT的第12个月发展为CR,另一组保持健康。分析了两组在第6个月PT活检中的基因表达谱,以鉴定出对第12个月CR发展具有预后价值的差异表达基因。结果:鉴定了10个基因,显示了两个患者组之间的差异表达谱。每个基因的15%到85%分位数范围完全分离。这组基因足以通过交叉验证正确预测17位患者中有15位(88%)的CR发生或不发生(仅根据其他患者的数据预测患者的发生)。此外,可以做出正确的预测,即活检正常的受者PT在接下来的6个月内会出现CR。结论:确定的表达模式似乎对肾CR的发展具有高度的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号